As cited by the business intelligence report titled ‘Global Breast Cancer Therapeutics Market Size study, By Product (Hormone Drugs, Chemotherapy Drugs, Targeted Drug Therapy), By Distribution Channel (Hospitals, Ambulatory Surgical Centers, Clinics, e-commerce, Retail Pharmacies), and Regional Forecasts 2020-2027’, available with Market Study Report, global breast cancer therapeutics market was worth USD 19.57 billion in 2019 and is projected to grow at 10.16% CAGR during 2020-2027, subsequently reaching a valuation of USD 42.44 billion by the end of the stipulated timeframe.
 

As per the findings of the report, growing prevalence of breast cancer due to late birth, excessive exposure to endogenous estrogens, late menopause, and early menarche is driving the industry growth. Additionally, introduction of advanced technologies in screening and diagnostic tests along with growing acceptance of therapeutic drugs are augmenting global breast cancer therapeutics market size.
 

Request sample copy of this Report: https://www.marketstudyreport.com/request-a-sample/3029617/
 

Moreover, increasing intake of alcohol, and rise in prevalence of obesity, mainly in postmenopausal women are further propelling market expansion. Further, rising adoption of oral birth control pills as well as hormone replacement therapy (HRT) has resulted in a significant spike in estrogen levels of women, rendering a positive impact on global breast cancer therapeutics market outlook.
 

On the contrary, unaffordable prices associated with breast cancer therapy will continue to hinder business development during the analysis timeframe. To compound the problem further, rise in cost of early and late-stage disease treatment, along with continuing care on a per-unit basis adding to the expenses impedes industry progression.
 

Based on product scope, global breast cancer therapeutics market is split into targeted drug therapy, chemotherapy drugs, and hormone drugs.
 

With regards to distribution channel, global breast cancer therapeutics market is bifurcated into retail pharmacies, clinics, ambulatory surgical centers, e-commerce, and hospitals.
 

From a regional viewpoint, Latin America, Europe, Asia-Pacific, and North America are the major contributors to the overall breast cancer therapeutics market growth. Among these, North America captured a majority of market share in 2018 and is anticipated to amass substantial returns over the forecast period. Factors such as rising geriatric population, escalating demand for tumor therapy, increasing research & development activities, and growing prevalence of breast cancer are fostering the regional industry growth.
 

Bristol-Myers Squibb, AstraZeneca plc, Eisai Co., Ltd., Genentech, Inc., Eli Lilly and Co., Genzyme Corp., GlaxoSmithKline plc, Novartis AG, Halozyme, Inc., and Pfizer, Inc. are the top organizations influencing worldwide breast cancer therapeutics market trends.